Patient No. | Age, y | Gender | Smoking | Stage | Tumor size | Wall | EGFR mutations | EGFR-TKI | PFS, mo | Efficacy | T790Â M |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | 62 | Male | Never | IV | 2.6Â cm | Thick | L858R mutation | Erlotinib | 4.7 | SD | Unknown |
2 | 71 | Male | Never | IV | 3.6Â cm | Thick | L858R mutation | Gefitinib | 3.3 | PR | Negative |
3 | 52 | Female | Never | IV | 2.2Â cm | Thick | L858R mutation | Gefitinib | 6.0 | PR | Negative |
4 | 44 | Male | Never | IV | 2.4Â cm | Thick | L858R mutation | Gefitinib | 9.6 | PR | Positive |
5 | 57 | Male | Never | IV | 2.0Â cm | Thick | L858R mutation | Gefitinib | 1.0 | PD | Negative |
6 | 50 | Male | Smoker | IV | 2.6Â cm | Thick | L858R mutation | Erlotinib | 4.2 | SD | Unknown |
7 | 76 | Female | Never | IV | 5.0Â cm | Thick | Exon 19 deletion | Gefitinib | 5.2 | SD | Unknown |
8 | 37 | Female | Never | IV | 2.8Â cm | Thin | Exon 19 deletion | Icotinib | 11.4 | PR | Unknown |
9 | 75 | Male | Never | IV | 2.2Â cm | Thin | Exon 19 deletion | Icotinib | 11.0 | PR | Positive |
10 | 61 | Female | Never | IV | 2.2Â cm | Thin | Exon 19 deletion | Gefitinib | 24.5 | PR | Positive |
11 | 47 | Male | Smoker | IV | 4.5Â cm | Thick | Exon 19 deletion | Gefitinib | 6.7 | PR | Negative |
12 | 48 | Male | Never | IV | 2.2Â cm | Thick | Exon 19 deletion | Gefitinib | 6.5 | SD | Negative |
13 | 51 | Male | Smoker | IV | 4.8Â cm | Thin | Exon 19 deletion | Icotinib | 9.7 | SD | Negative |
14 | 56 | Female | Never | Recurrent | 2.0Â cm | Thin | Exon 19 deletion | Gefitinib | 4.5 | PR | Positive |
15 | 39 | Male | Smoker | IV | 2.5Â cm | Thin | Exon 19 deletion | Icotinib | 3.0 | SD | Unknown |